SCH-51866

SCH-51866
Names
	IUPAC name (6aR,9aS)-5-Methyl-2-[4-(trifluoromethyl)benzyl]-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[2,1-b]purin-4(3H)-one
Identifiers
CAS Number	167298-74-0 ;
3D model (JSmol)	Interactive image;
ChemSpider	26377910;
IUPHAR/BPS	5270;
PubChem CID	15473392;
UNII	F8GU4PSP29 ;
	InChI InChI=1S/C19H18F3N5O/c1-26-17(28)15-16(27-13-4-2-3-12(13)23-18(26)27)25-14(24-15)9-10-5-7-11(8-6-10)19(20,21)22/h5-8,12-13H,2-4,9H2,1H3,(H,24,25)/t12-,13+/m1/s1 Key: JOSMPBVYYKRYLG-OLZOCXBDSA-N;
	SMILES CN1C(=O)C2=C(N=C(N2)CC3=CC=C(C=C3)C(F)(F)F)N4C1=N[C@H]5[C@@H]4CCC5;
Properties
Chemical formula	C19H18F3N5O
Molar mass	389.382 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

SCH-51866 is a phosphodiesterase inhibitor.^[1]^[2]

References

^ Lusche, DF; Kaneko, H; Malchow, D (18 April 2005). "cGMP-Phosphodiesterase Antagonists Inhibit Ca²⁺-Influx in Dictyostelium discoideum and Bovine Cyclic-Nucleotide-Gated-Channel". European Journal of Pharmacology. 513 (1–2): 9–20. doi:10.1016/j.ejphar.2005.01.047. PMID 15878705.
^ Beaumont, V; Park, L; Rassoulpour, A; Dijkman, U; Heikkinen, T; Lehtimaki, K; Kontkanen, O; Al Nackkash, R; Bates, GP; Gleyzes, M; Steidl, E; Ramboz, S; Murphy, C; Beconi, MG; Dominguez, C; Munoz-Sanjuan, I (13 February 2014). "The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease". PLOS Currents. 6. doi:10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca. PMC 3923778. PMID 24558637.

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

[1] Lusche, DF; Kaneko, H; Malchow, D (18 April 2005). "cGMP-Phosphodiesterase Antagonists Inhibit Ca²⁺-Influx in Dictyostelium discoideum and Bovine Cyclic-Nucleotide-Gated-Channel". European Journal of Pharmacology. 513 (1–2): 9–20. doi:10.1016/j.ejphar.2005.01.047. PMID 15878705.

[2] Beaumont, V; Park, L; Rassoulpour, A; Dijkman, U; Heikkinen, T; Lehtimaki, K; Kontkanen, O; Al Nackkash, R; Bates, GP; Gleyzes, M; Steidl, E; Ramboz, S; Murphy, C; Beconi, MG; Dominguez, C; Munoz-Sanjuan, I (13 February 2014). "The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease". PLOS Currents. 6. doi:10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca. PMC 3923778. PMID 24558637.

[1]

[2]

v t e Phosphodiesterase inhibitors
PDE1	MMPX SCH-51866 Vinpocetine
PDE2	BAY 60-7550 Carbazeran EHNA Oxindole PDP
PDE3	Adibendan Amrinone (inamrinone) Anagrelide Benafentrine Bucladesine Carbazeran Cilostamide Cilostazol Enoximone Ensifentrine Imazodan KMUP-1 Meribendan Milrinone Olprinone Parogrelil Pimobendan Pumafentrine Quazinone RPL-554 Siguazodan Trequinsin Vesnarinone Zardaverine
PDE4	Apremilast Arofylline Atizoram Benafentrine Catramilast CC-1088 CDP-840 CGH-2466 Cilomilast Cipamfylline Crisaborole Denbutylline Difamilast Drotaverine Ensifentrine Etazolate Filaminast Glaucine HT-0712 ICI-63197 Indimilast Irsogladine Lavamilast Lirimilast Lotamilast Luteolin Mesembrenone Mesembrine Mesopram Oglemilast Piclamilast Pumafentrine Revamilast Ro 20-1724 Roflumilast Rolipram Ronomilast RPL-554 RS-25344 Tetomilast Tofimilast YM-976 Zardaverine
PDE5	Acetildenafil Aildenafil Avanafil Beminafil Benzamidenafil Dasantafil Icariin Gisadenafil Homosildenafil Lodenafil Mirodenafil MY-5445 Nitrosoprodenafil Norcarbodenafil SCH-51866 Sildenafil Sulfoaildenafil T-0156 Tadalafil Udenafil Vardenafil
PDE7	BRL-50481
PDE9	BAY 73-6691 PF-04447943 Paraxanthine
PDE10	Balipodect Mardepodect MK-8189 Papaverine TC-E 5005 Tofisopam
PDE11	BC11-38
Non-selective	Aminophylline Caffeine Choline theophyllinate CPX Dipyridamole Doxofylline Enprofylline Ibudilast IBMX Luteolin Pentoxifylline Propentofylline Theobromine Theophylline Zaprinast
Unsorted	Diazepam Diprophylline DPCPX Furafylline Lisofylline MDL-12330A Moxaverine Oxagrelate Pentifylline Proxyphylline Quercetin Satigrel Tolafentrine Trapidil
See also: Receptor/signaling modulators